🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Do‐Youn Oh

Seoul National University Hospital

ORCID: 0000-0003-1663-9901

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer”.

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Journal of Clinical Oncology(2022)10.1200/jco.21.01604

N/A

4.0DataRank · unranked

230 citations

Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall +14 more

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations

Investigational New Drugs(2021)10.1007/s10637-021-01104-7

N/A

0.452DataRank · unranked

6 citations

Analía Azaro, Hendrik Tobias Arkenau, Do‐Youn Oh, Matthew D. Galsky, Sumanta K. Pal +6 more

O-2 Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)

Annals of Oncology(2023)10.1016/j.annonc.2023.04.017

N/A

0DataRank · unranked

5 citations

I. Bazin, Do‐Youn Oh, O. Zubkov, V. Breder, Li‐Yuan Bai +16 more